干细胞激酶抑制剂;Stemness kinase Inhibitors;;InformationAmcasertib (BBI503) Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.TargetsNanogIn vitroBBI-503 is orally-administered compound, which is designed to target CSC pathways in multiple tumour types.In vivoBBI503 inhibits Nanog and other cancer stem cell pathways by targeting kinases, and shows encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer.